Aishwarya Gopal

Dr. Aishwarya Gopal

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2020 in Rheumatology
Verified
Journal Article
Closed access
CKChengappa Kavadichanda
Chengappa Kavadichanda
SSSanket Shah
Sanket Shah
ADAnu Daber
Anu Daber
DBDevender Bairwa
Devender Bairwa
AMAnoop Mathew
Anoop Mathew
VNVir Singh Negi
Vir Singh Negi
Objectives: To assess acceptability of teleconsultation among the socioeconomically marginalized sections of patients with rheumatic and musculoskeletal diseases (RMDs), to identify the socioeconomic barriers in continuing rheumatology care during the COVID-19 crisis and to identify patients who could benefit by shifting to tele-rheumatology consultations. Methods: This was a cross sectional analytical study done at a tertiary care teaching hospital in India including patients with RMDs who were not on biological diseases modifying agents. Assessment of disease status, socioeconomic status and economic impact of COVID-19 was done via tele-consultation. Results: Out of the 680 patients satisfying inclusion criteria, 373 completed the study. The format was found easy by 334 (89.6%) of them and 284 (76.1%) considered tele-rheumatology better than in-person consultation. During the pre-COVID months, the median monthly per capita income of the families of our patients and cost of illness was Indian rupees (INR) 2000 (US$ 26) and INR 1685 (US$ 21.91), respectively. Families whose financial needs were met (OR = 0.38, 95% CI: 0.239, 0.598) or those with schooling upto at least secondary school (OR = 0.442, 95% CI: 0.260, 0.752) (P =0.002) were less likely to stop prescription drugs. In a hypothetical model, 289 (77.4%) could be successfully switched to tele-rheumatology follow-up. Conclusion: The acceptability of tele-rheumatology among socioeconomically marginalized patients with RMDs is good. During times of crisis, patients from poorer strata of society and lower educational background are likely to abruptly stop medications. Switching to a telemedicine-based hybrid model is likely to improve drug adherence with substantial savings on loss of pay and out of pocket expenditure.

20 April 2023 in Rheumatology
Verified
Journal Article
Closed access
PDF file
MGMamatha Gorijavolu
Mamatha Gorijavolu
DBDevender Bairwa
Devender Bairwa
SGSachit Ganapathy
Sachit Ganapathy
SDSaikumar Dunga
Saikumar Dunga
AGAishwarya Gopal
Aishwarya Gopal
CKChengappa Kavadichanda
Chengappa Kavadichanda
Objectives: To evaluate the relationship of thigh MRI (t-MRI) with manual muscle testing-8 (MMT-8), muscle enzymes and autoantibodies. To determine the causal and mediating factors resulting in poor recovery of MMT-8 in inflammatory myositis (IIM). Methods: This was a single-centre retrospective study in IIM patients. t-MRI was semi-quantitatively scored for muscle oedema, fascial oedema, muscle atrophy and fatty infiltration. Spearman correlation of t-MRI scores was done with muscle enzymes at baseline, and MMT-8 at baseline and on follow-up. Causal mediation analysis was performed with age, sex, symptom duration, autoantibodies, diabetes and BMI as independent variables, follow-up MMT-8 as dependent and t-MRI scores as mediating variables. Results: Baseline evaluation was done on 59 and follow-up on 38 patients. Median follow-up of the cohort was 31 (10–57) months. Baseline MMT-8 negatively correlated with muscle oedema (r = –0755), fascial oedema (r = –0.443) and muscle atrophy (r = –0.343). Creatinine kinase (r = 0.422) and aspartate transaminase (r = 0.480) positively correlated with muscle oedema. Follow-up MMT-8 correlated negatively with baseline atrophy (r = –0.497) and fatty infiltration (r = –0.531). On follow-up, MMT-8 males had positive total effect (estimate (95%CI)) via atrophy [2.93 (0.44, 4.89)] and fatty infiltration [2.08 (0.54, 3.71)]. Antisynthetase antibody had a positive total effect via fatty infiltration [4.50 (0.37, 7.59)]. Age had a negative total effect via atrophy [–0.09 (0.19, –0.01)] and fatty infiltration [–0.07 (–0.15, –0.01)]. Disease duration had a negative total effect via fatty infiltration [–0.18 (–0.27, –0.02)]. Conclusion: Baseline fatty infiltration and muscle atrophy resulting from older age, female sex, longer disease duration and absent anti-synthetase antibodies, partly mediate muscle recovery in IIM.

14 December 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
AGAishwarya Gopal
Aishwarya Gopal
CKChengappa Kavadichanda
Chengappa Kavadichanda
DBDevender Bairwa
Devender Bairwa
SSSanket Shah
Sanket Shah
SMSonal Mehra
Sonal Mehra
VNVir Singh Negi
Vir Singh Negi
Objectives: To assess the performance of clinical and biochemical parameters in identifying renal histopathology. To assess the performance of a combination of demographic, clinical, serological and histopathological parameters in determining renal response at one year. Methods: Data of biopsy-proven (ISN/RPS—2003 criteria) Lupus Nephritis (LN) were extracted from the institute database. Demographic, clinical and biochemical parameters at the time of biopsy were noted, and their associations with histopathological class, activity and chronicity scores were evaluated. Follow-up data at one year were collected. Complete, partial or no response (CR, PR, NR) for renal outcomes at one year and the predictors of NR were assessed. Results: Out of the 333 renal biopsies, 240 (71.8%) were Class III/IV. More patients with Class III/IV LN had hypertension (52.1%) and low eGFR (p < 0.001). Among Class III/IV, AS correlated weakly with UPCR (r = 0.31, p < 0.01), eGFR (r = −0.172; p < 0.01) and CS with eGFR (r = −0.212; p < 0.01). The presence of either hypertension, UPCR > 0.5 g/day, active urinary sediments or serum creatinine >1.3 g/dL had a sensitivity of >96% and specificity of <9% in detecting proliferative LN, crescents, interstitial inflammation and chronicity. NR was higher in males (aOR:3.9, 95% CI:1.4–11.0, p < 0.001), those with abnormal baseline creatinine (aOR: 1.9, 95% CI: 1.1–3.2, p < 0.001), higher renal SLEDAI (p < 0.05), higher AS, CS (p < 0.001) and interstitial inflammation (p < 0.005). In the binary logistic regression, the combination of male sex, baseline creatinine, UPCR and CS performed best in predicting NR (AUC: 0.762; 95% CI: 0.684–0.840, p < 0.001). Conclusions: Clinical and biochemical parameters alone have a poor specificity in identifying renal histopathology. A combination of demographic, clinical and histopathology parameters can better predict renal outcomes at one year.

15 October 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
DBDevender Bairwa
Devender Bairwa
CKChengappa Kavadichanda
Chengappa Kavadichanda
MAM. B. Adarsh
M. B. Adarsh
AGAishwarya Gopal
Aishwarya Gopal
VNVir Singh Negi
Vir Singh Negi

24 March 2025 in Rheumatology
Verified
Journal Article
Closed access
AGAishwarya Gopal
Aishwarya Gopal
CKChengappa Kavadichanda
Chengappa Kavadichanda
CMChristina Mary MARIASELVAM
Christina Mary MARIASELVAM
KHK T Harichandrakumar
K T Harichandrakumar
MTMolly Mary Thabah
Molly Mary Thabah
VNVir Singh Negi
Vir Singh Negi
Objectives: This study aimed to test whether immunosuppressant (IS) withdrawal is noninferior to glucocorticoid (GC) withdrawal in patients with SLE in remission. Methods: In this open-label, single-centre, randomized (1:1) controlled trial, we compared flare occurrence in stable SLE patients undergoing GC or IS tapering. Patients aged >18, on stable GC (prednisolone ≤7.5 mg/day) and maintenance non-biological IS for ≥3 years, in clinical remission for ≥1 year, were enrolled and assigned to taper GC or IS over 3 months. The primary endpoint was the proportion of patients experiencing a flare, defined by the SELENA-SLEDAI Flare Index (SFI) at 52 weeks. Patients in remission beyond 52 weeks were followed up to the maximum available follow-up duration beyond 104 weeks. Results: Between May and December 2021, 121 patients were randomized, and 117 (GC withdrawal, n = 58; IS withdrawal, n = 59) were included in the primary analysis. Flare occurred in 31% of the GC withdrawal group and 20.3% in the IS withdrawal group (risk difference, –10.6% [95% CI, −26.5 to 5.1]; P = 0.18), demonstrating the noninferiority of IS withdrawal. At maximum follow-up, 44.8% in the GC withdrawal group and 32.2% in the IS withdrawal group experienced a flare (risk difference, −12.6% [95% CI, −30.1 to 4.9]; P = 0.11), confirming the noninferiority of IS withdrawal at 2 years. Damage accrual was similar between the two groups at both endpoints. Conclusion: IS withdrawal is noninferior to GC withdrawal in SLE patients in long-term clinical remission. Personalized tapering strategies based on baseline damage and steroid exposure may optimize outcomes. Trial registration: The trial was registered with https://ctri.nic.in/, CTRI/2020/07/026712.

21 November 2023 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AGAishwarya Gopal
Aishwarya Gopal
CKChengappa Kavadichanda
Chengappa Kavadichanda
MGMohan Sreelekha Gayathri
Mohan Sreelekha Gayathri
MGMamatha Gorijavolu
Mamatha Gorijavolu
DBDevender Bairwa
Devender Bairwa
VNVir Singh Negi
Vir Singh Negi